Publications

 

Home
Faculty
Clinical
Research
Education
Training
Publications
Information
Search

You Are Here: Home > Publications

 
Infectious Diseases Faculty Publications: 1997-1999

Additional Publications Link: www.ncbi.nlm.nih.gov/pubmed/

  1. Aziz N, Nishanian P, Taylor JM, Mitsuyasa RT, Jacobson JM, Dezube BJ, Lederman MM, Detels R, Fahey JL Stability of plasma levels of cytokines and soluble activation markers in patients with human immunodeficiency virus infection. J Infect Dis 1999; 179:843-8.

  2. Baca-DeLancey RR, South MM, Ding X, and Rather PN. Escherichia coli genes regulated by cell to cell signaling. Proc. Natl. Acad.Sci. 1999; 96:4610-4614.

  3. Badley AD, Dockrell DH, Algeciras A, Ziesmar S, Landay A. Lederman MM, Connick E, Kessler H, Kuritzkes D, Lynch DH, Roche DH, Roche P, Yagita H, Paya CV. In vivo analysis of Fas/FasL interactions in HIV-infected patients. J Clin Invest 1998; 102:79-87.

  4. Balaji KN, Boom WH. Processing of Mycobacterium tuberculosis bacilli by human monocytes for CD4+ alphabeta and gammadelta T cells: role of particulate antigen. Infect Immun 1998; 66:98-106.

  5. Barditch-Crovo P, Noe D, Skowron G, Lederman MM, Kalayjian RC, Borum P, Buier R, Rowe WB, Goldberg D, Lietman P. A phase I/II evaluation of oral L-2-oxothiazolidine-4-carboxylic acid in asymptomatic patients infected with human immunodeficiency virus. J Clin Pharmacol 1998; 38:357-63.

  6. Blumstein DT, Armitage KB. Why do yellow-bellied marmots call? Anim Behav 1998; 56:1053-1055.

  7. Bonafede M, Rice LB. Emerging antibiotic resistance. J Lab Clin Med 1997; 130:558-66.

  8. Bonafede ME, Carias LL, Rice LB. Enterococcal transposon Tn5384: evolution of a composite transposon through cointegration of enterococcal and staphylococcal plasmids. Antimicrob Agents Chemother 1997; 41:1854-8.

  9. Bonomo RA, Aucott J, Salata RA. Oral Antibiotics in the Nineties: New Drugs and New Challenges in Primary Care. Front Biosci 1997; 2:e63-71.

  10. Bonomo RA, Korman N, Nagashima-Whalen L, Briggs J, Graham R, Salata RA. Pityriasis rubra pilaris: an unusual cutaneous complication of AIDS. Am J Med Sci 1997; 314:118-21.

     

    Return to top

  11. Bonomo RA, Rice D, Whalen C, Linn D, Eckstein E, Shlaes DM. Risk factors associated with permanent access-site infections in chronic hemodialysis patients. Infect Control Hosp Epidemiol 1997; 18:757-61.

  12. Bonomo RA, Jacobs M, Jacobs G, Graham R, Salata RA. Norwegian scabies and a toxic shock syndrome toxin 1-producing strain of Staphylococcus aureus endocarditis in a patient with trisomy 21 [see comments]. Clin Infect Dis 1998; 27:645-6.

  13. Bonomo RA, Briggs JM, Gross W, Hassan M, Graham RC, Butler WR, Salata RA. Mycobacterium celatum infection in a patient with AIDS [letter]. Clin Infect Dis 1998; 26:243-5.

  14. Bonomo RA, Rice LB. Emerging issues in antibiotic resistant infections in long-term care facilities. J Gerontol A Biol Sci Med Sci 1999; 54:B260-7.

  15. Bonomo RA, Rice LB. Inhibitor resistant class A beta-lactamases. Front Biosci 1999; 4:e34-41.

  16. Boom WH, Toossi Z. Differing susceptibilities of mice, guinea pigs and rabbits to Mycobacterium tuberculosis [letter]. Trends Microbiol 1998; 6:180-1.

  17. Burke DG, Emancipator SN, Smith MC, Salata RA. Histoplasmosis and kidney disease in patients with AIDS. Clin Infect Dis 1997; 25:281-4.

  18. Burke DG, Leonard DG, Imperiale TF, Valdez H, Karaman B, Schick E, Kalayjian RC. The utility of clinical and radiographic features in the diagnosis of cytomegalovirus central nervous system disease in AIDS patients. Mol Diagn 1999; 4:37-43.

  19. Canaday DH, Ziebold C, Noss EH, Chervenak KA, Harding CV, Boom WH. Activation of human CD8+ alpha beta TCR+ cells by Mycobacterium tuberculosis via an alternate class I MHC antigen-processing pathway. J Immunol 1999; 162:372-9.

  20. Carias LL, Rudin SD, Donskey CJ, Rice LB. Genetic linkage and cotransfer of a novel, vanB-containing transposon (Tn5382) and a low-affinity penicillin-binding protein 5 gene in a clinical vancomycin-resistant Enterococcus faecium isolate. J Bacteriol 1998; 180:4426-34.

     

    Return to top

  21. Chervenak KA, Lederman MM, Boom WH. Bacterial antigen activation of Vdelta1 and Vdelta2 gammadelta T cells of persons infected with human immunodeficiency virus type 1. J Infect Dis 1997; 175:429-33.

  22. Chien JW, Valdez H, McComsey G, McClernon D, St. Clair M, Lederman MM. Presence of mutation conferring resistance to lamivudine in plasma and cerebrospinal fluid of HIV-1-infected patients. J Acquir Immune Defic Syndr 1999; 21:277-80.

  23. Dezube BJ, Lederman MM, Chapman B, et al. The effect of tenidap on cytokines, acute-phase proteins, and virus load in human immunodeficiency virus (HIV)-infected patients: correlation between plasma HIV-1 RNA and proinflammatory cytokine levels. J Infect Dis 1997; 176:807-10.

  24. Donskey CJ, Schreiber JR, Jacobs MR, Shekar R, Salata RA, Gordon S, Whalen CC, Smith F, Rice LB. A polyclonal outbreak of predominantly VanB vancomycin-resistant enterococci in northeast Ohio. Northeast Ohio Vancomycin-Resistant Enterococcus Surveillance Program [In Process Citation]. Clin Infect Dis 1999; 29:573-9.

  25. Donskey CJ, Hanrahan JA, Hutton RA, Rice LB. Effect of parenteral antibiotic administration on persistence of vancomycin-resistant Enterococcus faecium in the mouse gastrointestinal tract. J Infect Dis 1999; 180:384-90.

  26. Fulton SA, Cross JV, Toossi ZT, Boom WH. Regulation of interleukin-12 by interleukin-10, transforming growth factor-beta, tumor necrosis factor-alpha, and interferon-gamma in human monocytes infected with Mycobacterium tuberculosis H37Ra. J Infect Dis 1998; 178:1105-14.

  27. Gardell LR, Whalen CA, Chattophadyay S, Cavallaro CA, Hubbell CL, Reid LD. Combination of naltrexone and fluoxetine on rats' propensity to take alcoholic beverage. Alcohol Clin Exp Res 1997; 21:1435-9.

  28. Gardell LR, Whalen CA, Chambers MD, Boswell KJ, Hubbell CL, Reid LD. Valproate reduces intake of alcoholic beverage among rats. Behav Pharmacol 1998; 9:683-9.

  29. Ghannoum MA, Rice LB. Antifungal Agents: Mode of Action, Mechanisms of Resistance, and Correlation of These Mechanisms with Bacterial Resistance. Clin Microbiol Rev 1999; 12:501-517.

  30. Goedert JJ, Erdman DD, Konkle BA, Jorok TJ, Lederman MM, Kleinert D, Mandalaki T, Kessler CM, Anderson LJ, Luban NL. Parvovirus B19 quiescence during the course of human immunodeficiency virus infection in persons with hemophilia. Am J Hematol 1997; 56:248-51.

     

    Return to top

  31. Gripshover BM, Aron DC. Status of endocrine disease with HIV infection. Curr Ther Endocrinol Metab 1997; 6:210-5.

  32. Gripshover BM, Valdez H, Salata RA, Lederman MM. Withdrawal of fluconazole suppressive therapy for thrush in patients responding to combination antiviral therapy including protease inhibitors [letter]. Aids 1998; 12:2513-4.

  33. Haas DW, Lederman MM, Clough LA, Wallis RS, Chernoff D, Crampton SL. Proinflammatory cytokine and human immunodeficiency virus RNA levels during early Mycobacterium avium complex bacteremia in advanced AIDS. J Infect Dis 1998; 177:1746-9.

  34. Hecker MT, Johnson JL, Whalen CC, Nyole S, Mugerwa RD, Ellner JJ. Two-step tuberculin skin testing in HIV-infected persons in Uganda. Am J Respir Crit Care Med 1997; 155:81-6.

  35. Hirsch CS, Toossi Z, Othieno C, Johnson JL, Schwander SK, Robertson S, Wallis RS, Edmonds K, Okwera A, Mugerwa R, Peters P, Ellner JJ. Depressed T-cell Interferon-g Responses in Pulmonary Tuberculosis: Analysis of Underlying Mechanisms and Modulation with Therapy. J Infect Dis 1999;180:2069-73.

  36. Hom DL, Johnson JL, Mugyenyi P, Byaruhanga R, Kityo C, Svilar GM, Vjecha M, Mugerwa RD, EllnerJJ. HIV-1 risk and vaccine acceptability in the Ugandan military. J Acquir Immun Defic Syndr Hum Retrovirol 1997; 15:375-380.

  37. Hornbuckle K, Chak A, Lazarus HM, Cooper GS, Kutteh LA, Gucalp R, Carlisle PS, Sparano J, Parker P, Salata RA. Determination and validation of a predictive model for Clostridium difficile diarrhea in hospitalized oncology patients. Ann Oncol 1998; 9:307-11.

  38. Jacobs GG, Johnson JL, Boom WH, Wallis RS, Whalen CC, Ginsberg AM. Tuberculosis vaccines: how close to human testing? Tuber Lung Dis 1997; 78:159-69.

  39. Johnson JL, Okwera A, Vjecha MJ, Byekwaso F, Nakibali J, Nyole S, Milberg J, Aisu T, Whalen CC, Mugerwa RD, Ellner JJ. Risk factors for relapse in human immunodeficiency virus type 1 infected adults with pulmonary tuberculosis. Int J Tuberc Lung Dis 1997; 1:446-53.

  40. Johnson JL, Nyole S, Okwera A, Whalen CC, Nsubuga P, Pekovic V, Huebner R, Wallis RS, Mugyenyi PN, Mugerwa RD, Ellner JJ. Instability of tuberculin and Candida skin test reactivity in HIV- infected Ugandans. The Uganda-Case Western Reserve University Research Collaboration. Am J Respir Crit Care Med 1998; 158:1790-6.

     

    Return to top

  41. Johnson JL, Shiratsuchi H, Toossi Z, Ellner JJ. Altered IL-1 expression and compartmentalization in monocytes from patients with AIDS stimulated with Mycobacterium avium complex. J Clin Immunol 1997;17:387-395.

  42. Johnson JL, Vjecha MJ, Okwera A, Hatanga E, Byekwaso F, Wolski K, Aisu T, Whalen CC, Huebner R, Mugerwa RD, Ellner JJ. Impact of human immunodeficiency virus type-1 infection on the initial bacteriologic and radiographic manifestations of pulmonary tuberculosis in Uganda. Makerere University-Case Western Reserve University Research Collaboration. Int J Tuberc Lung Dis 1998; 2:397-404.

  43. Justice AC, Weissman S. The Survival Experience of Older and Younger Adults with AIDS: Is There a Growing Gap in Survival? Research on Aging, 1998;20(6): 665-685.

  44. Kaushal S, Landay AL, Lederman MM, et al. Increases in T cell telomere length in HIV infection after antiretroviral combination therapy for HIV-1 infection implicate distinct population dynamics in CD4+ and CD8+ T cells [see comments]. Clin Immunol 1999; 92:14-24.

  45. Lederman MM, Connick E, Landay A, et al. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis 1998; 178:70-9.

  46. Lederman MM, Valdez H. Cytotoxic T-cell activity and progression of HIV disease: abstract and commentary. Jama 1998; 279:242.

  47. Macinga DR, Paradise MR, Parojcic MM, and Rather PN. Activation of the 2'-N-acetyltransferase gene (aac(2')-Ia) in Providencia stuartii by an interaction of AarP with the promoter region. Antimicrob. Agents Chemother. 1999; 43:1769-1772.

  48. Macinga DR, Cook G, Poole RK, and Rather PN. Identification and characterization of aarF, a locus required for the production of ubiquinone in Escherichia coli and Providencia stuartii and for expression of the 2'-N-acetyltransferase. J. Bacteriol. 1998; 180:128-135.

  49. Mudido PM, Guwatudde D, Nakakeeto MK, Bukenya GB, Nsamba D, Johnson JL, Mugerwa RD, Ellner JJ. The effect of bacille Calmette-Guerin vaccination at birth on tuberculin skin test reactivity in Ugandan children [In Process Citation]. Int J Tuberc Lung Dis 1999; 3:891-5.

  50. Okwera A, Johnson JL, Vjecha MJ, Wolski K, Whalen CC, Hom D, Huebner R, Mugerwa RD, Ellner JJ. Risk factors for adverse drug reactions during thiacetazone treatment of pulmonary tuberculosis in human immunodeficiency virus infected adults. Int J Tuberc Lung Dis 1997; 1:441-5.

     

    Return to top

  51. Olds GR, King C, Hewlett J, Olveda R, Wu G, Ouma J, Peters P, McGarvey S, Odhiambo O, Koech D, Liu CY, Aligui G, Gachihi G, Kombe Y, Parraga I, Ramirez B, Whalen CC, Horton RJ, Reeve D. Double-blind placebo-controlled study of concurrent administration of albendazole and praziquantel in schoolchildren with schistosomiasis and geohelminths. J Infect Dis 1999; 179:996-1003.

  52. Othieno C, Hirsch CS, Hamilton BD, Wilkinson K, Ellner JJ, Toossi Z. Interaction of mycobacterium tuberculosis-induced transforming growth factor beta1 and interleukin-10 [In Process Citation]. Infect Immun 1999; 67:5730-5.

  53. Paradise MR, Cook GR, Poole RK, and Rather PN. aarE, a homolog of ubiA is required for transcription of the aac(2')-Ia gene in Providencia stuartii. Antimicrob. Agents. Chemother. 1998; 42:959-962.

  54. Patki AH, Georges DL, Lederman MM. CD4+-T-cell counts, spontaneous apoptosis, and Fas expression in peripheral blood mononuclear cells obtained from human immunodeficiency virus type 1-infected subjects. Clin Diagn Lab Immunol 1997; 4:736-41.

  55. Patki AH, Purvis SF, Valdez H, Spritzler J, Connick E, Kuritzkes, DR, Kessler H, Fox L, St. Clair M, Landay A, Lederman MM. HIV infection perturbs DNA content of lymphoid cells: partial correction after 'suppression' of virus replication. Aids 1999; 13:1177-85.

  56. Pekovic V, Mayanja H, Vjecha M, Johnson J, Okwera A, Nsubuga P, Mugerwa R, Ellner J, Whalen C. Comparison of three composite compliance indices in a trial of self- administered preventive therapy for tuberculosis in HIV-infected Ugandan adults. Uganda-Case Western Reserve University Research Collaboration. J Clin Epidemiol 1998; 51:597-607.

  57. Powderly WG, Landay A, Lederman MM. Recovery of the immune system with antiretroviral therapy: the end of opportunism? Jama 1998; 280:72-7.

  58. Purvis SF, Katongole-Mbidde E, Johnson JL, Leonard DGB, Byabazaire N, Luckey C, Schick HE, Elmets CA, Giam CZ. High incidence of Kaposi's sarcomaassociated herpesvirus (KSHV) and EpsteinBarr virus in tumor lesions and peripheral blood mononuclear cells from patients with Kaposi's sarcoma in Uganda. J Infect Dis 1997;175:947-950.

  59. Quinones-Mateu ME, Mas A, Lain de Lera T, Soriano V, Alcami J, Lederman MM, Domingo E. LTR and tat variability of HIV-1 isolates from patients with divergent rates of disease progression. Virus Res 1998; 57:11-20.

  60. Ramachandra L, Sramkoski RM, Canaday DH, Boom WH, Harding CV. Flow analysis of MHC molecules and other membrane proteins in isolated phagosomes. J Immunol Methods 1998; 213:53-71.

     

    Return to top

  61. Ramachandra L, Chu RS, Askew D, Noss EH, Canaday DH, Potter NS, Johnson A, Krieg AM, Nedrud JG, Boom WH, Harding CV. Phagocytic antigen processing and effects of microbial products on antigen processing and T-cell responses. Immunol Rev 1999; 168:217-39.

  62. Rather PN, Solinsky K, Paradise MR, and Parojcic MM. aarC, an essential gene involved in the density dependent regulation of the 2'-N-acetyltransferase in Providencia stuartii. J. Bacteriol 1997; 179:2267-2273.

  63. Rather PN, Paradise MR, and Parojcic MM. An extracellular factor regulating expression of the chromosomal aminoglycoside 2'-N-acetyltransferase in Providencia stuartii. Antimicrob. Agents Chemother. 1997; 41:1749-1754

  64. Rather PN, Paradise M, and Parojcic MM. A regulatory cascade involving AarG, a putative sensor kinase controls expression of the 2'-N-acetyltransferase and an intrinsic multiple antibiotic resistance (Mar) response in Providencia stuartii. Mol. Microbiol 1998; 28:1345-1353.

  65. Rather PN. Origins of the aminoglycoside modifying enzymes. Drug Resistance Updates. 1998; 5:285-291.

  66. Rather PN, and Macinga DR. The chromosomal 2'-N-acetyltransferase of Providencia stuartii: physiological functions and genetic regulation. Frontiers in Bioscience. 1998; 4:132-140

  67. Rather PN, Baca-DeLancey RR0, and Ding X. Providencia stuartii genes activated by cell-cell signaling and identification of a gene required for the production or activity of an extracellular factor. J. Bacteriol.1999; 181:7185-7191.

  68. Rice LB, Carias LL, Donskey CL, Rudin SD. Transferable, plasmid-mediated vanB-type glycopeptide resistance in Enterococcus faecium. Antimicrob Agents Chemother 1998; 42:963-4.

  69. Rice LB. Tn916 family conjugative transposons and dissemination of antimicrobial resistance determinants. Antimicrob Agents Chemother 1998; 42:1871-7.

  70. Rice LB, Carias LL. Transfer of Tn5385, a composite, multiresistance chromosomal element from Enterococcus faecalis. J Bacteriol 1998; 180:714-21.

     

    Return to top

  71. Rice LB. Successful interventions for gram-negative resistance to extended- spectrum beta-lactam antiobiotics. Pharmacotherapy 1999; 19:120S-128S; discussion 133S-137S.

  72. Rice LB. A silver bullet for colonization and infection with methicillin- resistant Staphylococcus aureus still eludes us [editorial; comment]. Clin Infect Dis 1999; 28:1067-70.

  73. Rojas RE, Balaji KN, Subramanian A, Boom WH. Regulation of Human CD4(+) alphabeta T-Cell-Receptor-Positive (TCR(+)) and gammadelta TCR(+) T-Cell Responses to Mycobacterium tuberculosis by Interleukin-10 and Transforming Growth Factor beta. Infect Immun 1999; 67:6461-6472.

  74. Sadek MI, Sada E, Toossi Z, Schwander SK, Rich EA. Chemokines induced by infection of mononuclear phagocytes with mycobacteria and present in lung alveoli during active pulmonary tuberculosis. Am J Respir Cell Mol Biol 1998; 19:513-21.

  75. Sang DK, Ouma JH, John CC, Whalen CC, King CL, Mahmoud AA, Heinzel FD. Increased levels of soluble interleukin-4 receptor in the sera of patients with visceral leishmaniasis. J Infect Dis 1999; 179:743-6.

  76. Schwander SK, Dietrich M, Mugyenyi P, Kityo C. Okwera A, Johnson J, Nsubuga P, Ruesch--Gerdes S, Whalen C. Clinical course of human immunodeficiency virus type 1 associated pulmonary tuberculosis during short-course antituberculosis therapy. East Afr Med J 1997; 74:543-8.

  77. Schwander SK, Torres M, Sada E, Carranza C, Ramos E, Tary-Lehmann M, Wallis RS, Sierra J and Rich EA. Enhanced responses to Mycobacterium tuberculosis Antigens by Alveolar Lymphocytes during Active Pulmonary Tuberculosis. J Infect Dis 1998;178:1434-45.

  78. Shapiro HM, Lederman M, Connick E, Kessler H, Kuritzkes DR, Landay AL. Small differences in CD4+ T-cell production may go unnoticed [letter]. Aids 1999; 13:290-1.

  79. Silver RF, Li Q, Boom WH, Ellner JJ. Lymphocyte-dependent inhibition of growth of virulent Mycobacterium tuberculosis H37Rv within human monocytes: requirement for CD4+ T cells in purified protein derivative-positive, but not in purified protein derivative-negative subjects. J Immunol 1998; 160:2408-17.

  80. Silver RF, Li Q, and Ellner JJ. "Expression of virulence of Mycobacterium tuberculosis within human monocytes: virulence correlates with intracellular growth and induction of TNFa, but not with evasion of lymphocyte-dependent monocyte effector functions", Infection and Immunity, 66: 1190-1199, 1998.

     

    Return to top

  81. Tan JS, Canaday DH, Boom WH, Balaji KN, Schwander SK, Rich EA. Human alveolar T lymphocyte responses to Mycobacterium tuberculosis antigens: role for CD4+ and CD8+ cytotoxic T cells and relative resistance of alveolar macrophages to lysis. J Immunol 1997; 159:290-7.

  82. Toltzis P, Hoyen C, Spinner-Block S, Salvator AE, Rice LB. Factors that predict preexisting colonization with antibiotic-resistant gram-negative bacilli in patients admitted to a pediatric intensive care unit. Pediatrics 1999; 103:719-23.

  83. Toossi Z, Mincek M, Seeholtzer E, Fulton SA, Hamilton BD, Hirsch CS. Modulation of IL-12 by transforming growth factor-beta (TGF-beta) in Mycobacterium tuberculosis-infected mononuclear phagocytes and in patients with active tuberculosis. J Clin Lab Immunol 1997; 49:59-75.

  84. Tsukaguchi K, de Lange B, Boom WH. Differential regulation of IFN-gamma, TNF-alpha, and IL-10 production by CD4(+) alphabetaTCR+ T cells and vdelta2(+) gammadelta T cells in response to monocytes infected with Mycobacterium tuberculosis-H37Ra. Cell Immunol 1999; 194:12-20.

  85. Valdez H, Lederman MM. Cytokines and cytokine therapies in HIV infection. AIDS Clin Rev 1997:187-228.

  86. Valdez H, Gripshover BM, Salata RA, Lederman MM. Resolution of azole-resistant oropharyngeal candidiasis after initiation of potent combination antiretroviral therapy [letter]. Aids 1998; 12:538.

  87. Valdez H, Al-Harthi L, Landay A, Lederman MM. Rationale for immune-based therapies for HIV-1 infection. J Lab Clin Med 1998; 131:197-206.

  88. Valdez H, Lederman MM, Woolley I, Walker CJ, Vernon LT, Hise A, Gripshover BM. Human immunodeficiency virus 1 protease inhibitors in clinical practice: predictors of virological outcome. Arch Intern Med 1999; 159:1771-6.

  89. Valdez H, Purvis SF, Lederman MM, Fillingame M, Zimmerman PA. Association of the CCR5delta32 mutation with improved response to antiretroviral therapy [letter]. Jama 1999; 282:734.

  90. Valdez H, Purvis S, Asaad R, Valerio I, Sha BE, Landay AL, Lederman MM. Levels of proinflammatory cytokines in plasma after pneumoccoccal immunization in human immunodeficiency virus type 1-infected patients. Clin Diagn Lab Immunol 1999; 6:427-8.

     

    Return to top

  91. Vanham G, Toossi Z, Hirsch CS, Wallis RS, Schwander SK, Rich EA, Ellner JJ. Examining a paradox in the pathogenesis of human pulmonary tuberculosis: immune activation and suppression/anergy. Tuber Lung Dis 1997; 78:145-58.

  92. Venkataprasad N, Jacobs MR, Johnson JL, Klopman G, Ellner JJ. Activity of new quinolones against intracellular Mycobacterium avium in human monocytes. J Antimicrob Chemother 1997;40:841-845.

  93. Waibale P, Bowlin SJ, Mortimer EA, Jr., Whalen C. The effect of human immunodeficiency virus-1 infection and stunting on measles immunoglobulin-G levels in children vaccinated against measles in Uganda. Int J Epidemiol 1999; 28:341-6.

  94. Wallis RS, Lederman HM, Spritzler J, Devers JL, Georges D, Weinberg A, Stehn S, Lederman MM. Measurement of induced cytokines in AIDS clinical trials using whole blood: a preliminary report. ACTG Inducible Cytokines Focus Group. AIDS Clinical Trials Group. Clin Diagn Lab Immunol 1998; 5:556-60.

  95. Wallis RS, Johnson JL, Okwera A, Nsubuga P, Whalen CC, Mugerwa RD, Ellner JJ. Pentoxifylline in human immunodeficiency virus- positive tuberculosis: safety at 4 years [letter]. J Infect Dis 1998; 178:1861.

  96. Wallis RS, Perkins M, Phillips M, Joloba M, Demchuk M, Namale A, Johnson J, Williams D, Wolski K, Teixeira L, Dietze R, Mugerwa R, Eisenach K, and Ellner J. Induction of M. tuberculosis antigen 85 in sputum: A determinant of outcome in pulmonary tuberculosis. 1998. J Infect Dis, 178:1115-21.

  97. Wallis RS, Patil SA, Cheon SH, Edmonds K, Phillips M, Perkins MD, Joloba M, Namale A, Johnson JL, Teixeira L, Dietze R, Siddiqi S, Mugerwa RD, Eisenach K, and Ellner JJ. 1999. Drug tolerance in M. tuberculosis. Antimicrob Agents Chemother 43(11):2600-6.

  98. Weissman SB, Purvis S, Valdez H. Interferon-gamma Treatment of Macrolide-Resistant Mycobacterium Avium Infection in a Patient with AIDS.IDCP,1998;7:292-294.

  99. Weissman SB, Sinclair GI, Green CL, Fissell WH. Hydroxyurea-induced hepatitis in human immunodeficiency virus-positive patients. Clin Infect Dis 1999; 29:223-4.

  100. Whalen CC, Johnson JL, Okwera A, Hom DL, Huebner R, Mugyenyi P, Mugerwa RD, Ellner JJ. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration [see comments]. N Engl J Med 1997; 337:801-8.

     

    Return to top

  101. Whalen C, Horsburgh CR, Jr., Hom D, Lahart C, Simberkoff M, Ellner J. Site of disease and opportunistic infection predict survival in HIV- associated tuberculosis. Aids 1997; 11:455-60.

  102. Woolley I, Valdez H, Walker C, Landay A, Zdunek D, Hess G, Lederman MM. Hepatitis G virus RNA is common in AIDS patients' plasma but is not associated with abnormal liver function tests or other clinical syndromes. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19:408-12.

  103. Woolley I, Valdez H, Walker C, Landay A, Zdunek D, Hess G. Lederman MM. High prevalence of hepatitis G virus RNA and antibody to probable viral envelope protein but not both in AIDS patients' plasma [letter]. Aids 1998; 12:530-1.

  104. Wu H, Kuritzkes DR, McClernon DR, Kessler H, Connick E, Landay A, Spear G, Heath-Chiozzi M, Rousseau F, Fox L, Spritzler J, Leonard JM, Lederman MM. Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration, and virologic end points. J Infect Dis 1999; 179:799-807.

  105. Paterson, DL, Rice LB, Bonomo, RA.  A rapid method of extraction and analysis of extended spectrum â-lactamases from clinical strains of Klebsiella pneumoniae.  Clinical Microbiology and Infection (2002).

  106. Odeh R. S. Kelkar , P.Schrecenberger, A.M. Hujer, RA Bonomo, J.P. Quinn.  Broad resistance due to plasmid mediated AmpC b-lactamases in Escherichia coli isolates in Chicago. Clinical Infectious Diseases, July 15, 2002 .

  107. Hujer AM, MS Helfand, M.G.P. Page, B. Yeiser, RA Bonomo Development of a sensitive and specific enzyme linked immunosorbent assay detecting and quantifying CMY-2 and SHV b-lactamases. J Clin Microbiol. 2002 . Jun;40(6):1947-57.

  108. Lange CG, Lederman MM, Sierra Madero J, Medvik K, Asaad R, Pacheko C, Carranza C, Valdez H. Impact of Suppression of Viral Replication by Highly Active Antiretroviral Therapy on Immune Function and Phenotype in Chronic HIV Infection. Journal of Acquired Immune Deficiency Syndromes 2002;30:33-40.

  109. Valdez H, Carlson LN, Post AB, Heeger PS, Lederman MM, Lehmann PV, Anthony DD. HIV Long-Term Nonprogressors maintain brisk CD8+ T-cell responses to other viral antigens. AIDS 2002; 16(8): 1113-8.

  110. Sha BE, Valdez H, Gelman RS, Landay AL, Agosti J, Mitsuyasu R, Pollard RB, Mildvan D, Namkung A, Ogata-Arakaki DM, Fox L, Estep S, Erice A, Walker RE, Bancroft L, Lederman MM. Effect Of Etanercept (Enbrel*) On Interleukin-6 (Il-6), Tumor Necrosis Factor-Alpha (Tnf-a), And Markers Of Immune Activation In Hiv-Infected Subjects Receiving Interleukin-2. AIDS Research and Human Retroviruses 2002; 18: 661-5.

  111. McComsey G, Valdez H, Lederman MM. Successful Maintenance of HIV Viral Suppression on Efavirenz Monotherapy. International Pediatrics 2002;17:94-5.

 
 

[Top] [ Home ] [ Faculty ] [ Clinical ] [ Research ] [ Education ] [ Training ] [ Publications ] [ Information ] [ Search ]

Case Western Reserve University, University Hospitals of Cleveland, and Veterans Administration Medical Center, Cleveland, Ohio